Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study

American Journal of Nephrology

Volumn 42, Issue 2, 2015, Pages 107-114

  Roussel, Ronan ^a,b,c   Matallah, Nadia ^a,b,c   Bouby, Nadine ^a,d   El Boustany, Ray ^a,d   Potier, Louis ^a,b,c   Fumeron, Frédéric ^a,b   Mohammedi, Kamel ^a,c   Balkau, Beverley ^e,f   Marre, Michel ^a,c   Bankir, Lise ^a,d   Velho, Gilberto ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Copeptin; Creatinine clearance; Epidemiology; Nephropathy progression; Vasopressin

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COPEPTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; GLYCOPEPTIDE; VASOPRESSIN DERIVATIVE;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; FRANCE; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; SEX DIFFERENCE;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; CREATININE; DISEASE PROGRESSION; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SEX FACTORS; VASOPRESSINS;

EID: 84941247629     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000439061     Document Type: Article

References (36)

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW: Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-272.
2. KDIGO Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
3. Torres VE, Bankir L, Grantham JJ: A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1140-1150.
4. Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Weir MA, Garg AX: The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. BMJ Open 2013; 3:e003666.
5. Wang CJ, Grantham JJ, Wetmore JB: The medicinal use of water in renal disease. Kidney Int 2013; 84: 45-53.
6. Strippoli GF, Craig JC, Rochtchina E, Flood VM, Wang JJ, Mitchell P: Fluid and nutrient intake and risk of chronic kidney disease. Nephrology (Carlton) 2011; 16: 326-334.
7. Sontrop JM, Dixon SN, Garg AX, Buendia-Jimenez I, Dohein O, Huang SH, Clark WF: Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol 2013; 37: 434-442.
8. Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, Salvadori M, Garg AX: Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 2011; 6: 2634-2641.
9. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119.
10. Morgenthaler NG: Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010;(16 suppl 1):S37-S44.
11. Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG: Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 2014; 99: 4656-4663.
12. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Müller B, Keller U, Christ-Crain M: Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007; 92: 3973-3978.
13. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J: Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states. J Clin Endocrinol Metab 2011; 96: 1046-1052.
14. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010; 77: 29-36.
15. Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 361-368.
16. Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R: Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 2013; 36: 3639-3645.
17. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, Fumeron F, Froguel P, Vaxillaire M, Cauchi S, Ducimetière P, Eschwège E: Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2008; 31: 2056-2061.
18. Konrat C, Mennen LI, Cacès E, Lepinay P, Rakotozafy F, Forhan A, Balkau B; D.E.S.I.R. Study Group: Alcohol intake and fasting insulin in French men and women. The D.E.S.I.R. Study. Diabetes Metab 2002; 28: 116-123.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
20. Marre M, Claudel JP, Ciret P, Luis N, Suarez L, Passa P: Laser immunonephelometry for routine quantification of urinary albumin excretion. Clin Chem 1987; 33(2 pt 1):209-213.
21. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S: High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41: 962-971.
22. Plischke M, Kohl M, Bankir L, Shayganfar S, Handisurya A, Heinze G, Haas M: Urine osmolarity and risk of dialysis initiation in a chronic kidney disease cohort - a possible titration target? PLoS One 2014; 9:e93226.
23. Ponte B, Pruijm M, Ackermann D, Vuistiner P, Guessous I, Ehret G, Alwan H, Youhanna S, Paccaud F, Mohaupt M, Péchère-Bertschi A, Vogt B, Burnier M, Martin PY, Devuyst O, Bochud M: Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study. J Am Soc Nephrol 2015; 26: 1415-1425.
24. Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, Struck J, de Jong PE, Bilo HJ, Kleefstra N, Gansevoort RT: Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 2013; 56: 1680-1688.
25. Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP: Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 2013; 61: 420-429.
26. Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009; 88: 561-567.
27. Bankir L, Bouby N, Ritz E: Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013; 9: 223-239.
28. Bouby N, Ahloulay M, Nsegbe E, Déchaux M, Schmitt F, Bankir L: Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996; 7: 842-851.
29. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N, Bankir L: Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the reninangiotensin system. Nephrol Dial Transplant 2003; 18: 497-506.
30. Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Trang-Tan MM, Bankir L: Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci U S A 1999; 96: 10397-10402.
31. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L: Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18: 1755-1763.
32. Bouby N, Bachmann S, Bichet D, Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258(4 pt 2):F973-F979.
33. Sugiura T, Yamauchi A, Kitamura H, Matsuoka Y, Horio M, Imai E, Hori M: High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int 1999; 55: 1800-1810.
34. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP: Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006; 17: 2220-2227.
35. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19: 102-108.
36. Botev R, Mallié JP, Wetzels JF, Couchoud C, Schück O: The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. Clin J Am Soc Nephrol 2011; 6: 937-950.